ArticleCentral-European journal of immunology2021
Euxanthone improves cognitive impairment by attenuating mitochondrial fragmentation and suppressing oxidative stress.
Article in Central-European journal of immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 3 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mitophagy and apoptosis significantly contribute to the dynamics of mitochondria and their associated disorders. Euxanthone (EUX) is a xanthone derivative that exhibits several therapeutic effects at a preclinical level. However, its impact in a cerebral ischemia and reperfusion model has not been investigated. The investigation aimed to determine the protective effect of EUX in cerebral ischemia and cognitive impairment and explore its underlying mechanism. A bilateral common carotid artery occlusion (BCCAO) model was employed in the present work. Forty male ICR mice were divided into four groups - Sham, BCCAO, EUX30 (BCCAO + EUX 30 mg/kg) and EUX60 (BCCAO + EUX 60 mg/kg). The mice were then subjected to a Morris water maze study for investigation of learning and memorizing capabilities. The hippocampal specimens of mice were quantified for the presence of oxidative markers. Homogenized hippocampal fractions were determined for the levels of Beclin-1, LC3, p53, Bax, caspase-3, Bnip3, DRP1 and Nrf2. The present investigation revealed that BCCAO caused oxidative stress in mitochondria and led to mitochondrial breakdown. EUX administration markedly attenuated BCCAO triggered mitochondrial stress and related breakdown. EUX treatment normalized Bnip3, Beclin1, Pink1, Parkin, p53, Bax, caspase-3, and LC3 II/I. Altogether, EUX treatment modulated mitophagy and apoptosis induced by mitochondrial stress mediated by mitochondrial fragmentation, due to cerebral ischemia and reperfusion injury.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.